EBS News and Press, Emergent Biosolutions Inc.

GAITHERSBURG, Md., March 03, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced the appointment of John D. Fowler, Jr. to its board of directors effective March 1, 2026. Mr. Fowler brings more than three decades of leadership experience across the healthcare and finan...

2026-02-28 09:47:19 ET Thesis Emergent BioSolutions Inc. ( EBS ) closed about 27% lower on Friday. I think it’s safe to say that the slide was driven less by the 2025 results but more by a major negative reset in 2026 expectations . Management guided to just $720 ...

2026-02-27 10:32:41 ET More on Emergent Biosolutions Emergent BioSolutions Inc. (EBS) Q4 2025 Earnings Call Prepared Remarks Transcript Emergent BioSolutions Inc. 2025 Q4 - Results - Earnings Call Presentation Emergent BioSolutions Inc. (EBS) Presents at 44th Annual ...

2026-02-26 23:58:29 ET More on Emergent Biosolutions Emergent BioSolutions Inc. (EBS) Q4 2025 Earnings Call Prepared Remarks Transcript Emergent BioSolutions Inc. 2025 Q4 - Results - Earnings Call Presentation Emergent BioSolutions Inc. (EBS) Presents at 44th Annual ...

2026-02-26 23:58:01 ET Emergent BioSolutions Inc. (EBS) Q4 2025 Earnings Call February 26, 2026 5:00 PM EST... Read the full article on Seeking Alpha For further details see: Emergent BioSolutions Inc. (EBS) Q4 2025 Earnings Call Prepared Remarks Transcript

2026-02-26 16:37:09 ET More on Emergent Biosolutions Emergent BioSolutions Inc. (EBS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript Emergent BioSolutions Inc. (EBS) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow Emergent ...

2026-02-26 16:09:48 ET More on Emergent Biosolutions Emergent BioSolutions Inc. (EBS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript Emergent BioSolutions Inc. (EBS) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow Emergent ...

Fourth Quarter 2025 Total Revenues of $148.7 million; Full Year 2025 Total Revenues of $742.9 million Fourth Quarter 2025 Net Loss of $54.6 million and Net Loss Margin of 37% Full Year 2025 Net Income of $52.6 million versus a Net Loss of $190.6 million in the prior year Full Year 2025 Net Inc...

WINNIPEG, Manitoba, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions (NYSE: EBS) today announced a series of new contracts and a contract modification with the Public Health Agency of Canada (PHAC) and the Department of National Defence (DND) to deliver critical medical countermeasures to ...

GAITHERSBURG, Md., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that its Board of Directors authorized the repurchase of up to $50 million of the company’s common stock on or before March 31, 2027. This authorization replaces the prior repurchase...